ICH E9 guideline 'Statistical principles for clinical trials': a case study - Response

被引：4
|
作者：
Brown, DJ [1 ]
机构：
[1] Med Control Agcy, London SW8 5NQ, England
来源：
STATISTICS IN MEDICINE | 2003年 / 22卷 / 01期
关键词：
D O I：
10.1002/sim.1329
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：13 / 17
页数：5
相关论文
共 50 条
  • [31] The all randomized/full analysis set (ICH E9) - May patients be excluded from the analysis?
    Lange, S
    DRUG INFORMATION JOURNAL, 2001, 35 (03): : 881 - 891
  • [32] 从审评角度谈适用ICH E9(R1)的初步考虑
    李新旭
    周军
    唐智敏
    卢明亮
    谭明敏
    王景朝
    中国食品药品监管 , 2022, (05) : 40 - 47
  • [33] Statistical principles for omics-based clinical trials
    Sachs, Michael C.
    CHINESE CLINICAL ONCOLOGY, 2015, 4 (03)
  • [34] Statistical Design and Analysis of Clinical Trials: Principles and Methods
    Gu, Hui
    BIOMETRICS, 2018, 74 (04) : 1523 - 1523
  • [35] Essential statistical principles of clinical trials of pain treatments
    Dworkin, Robert H.
    Evans, Scott R.
    Mbowe, Omar
    McDermott, Michael P.
    PAIN REPORTS, 2021, 6 (01)
  • [36] Choice of control group in efficacy-showing clinical trials in Japan: Does the ICH-E10 guideline change conventions?
    Ono S.
    Shibata T.
    Morikawa T.
    Uesaka H.
    Nagasawa T.
    International Journal of Pharmaceutical Medicine, 2002, 16 (2) : 79 - 86
  • [37] Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
    Qu, Yongming
    Lipkovich, Ilya
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (05) : 984 - 988
  • [38] The ICH E9(R1) Estimand Framework in the Context of Real-World Data and Observational Studies
    Husemoen, Lotte
    Morga, Antonia
    Remiro-Azocar, Antonio
    Kleinjung, Frank
    Rantell, Khadija Rerhou
    Besseghir, Amel
    Rosettani, Barbara
    Allignol, Arthur
    Vaitsiakhovich, Tatsiana
    Polavieja, Pepa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 553 - 554
  • [39] Are gastroprotective drugs useful for gastric ulcer healing: Re-evaluation using current ICH E9 guidelines
    Higuchi K.
    Watanabe T.
    Tanigawa T.
    Shiba M.
    Tominaga K.
    Fujiwara Y.
    Oshitani N.
    Arakawa T.
    Inflammopharmacology, 2007, 15 (1) : 18 - 21
  • [40] Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic
    Yongming Qu
    Ilya Lipkovich
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 984 - 988
12345